High-Sensitivity Troponin T and Copeptin in Non-ST Acute Coronary Syndromes: Implications for Prognosis and Role of hsTnT and Copeptin in Non-STEACS

Table 3

Association of elevated hsTnT levels with clinical features. Logistic regression analyses. Cutoff point for hsTnT = 0.013 ng/mL.

	Univariate		Multivariate
Condition	OR (95% CI)	𝑃	OR (95% CI)	𝑃
age > 65 years	2.40 (1.21–5.12)	0.024	2.42 (0.78–7.53)	0.127
Previous non-STEACS	1.84 (0.69–4.86)	0.221
Female sex	0.35 (0.15–0.86)	0.022	0.17 (0.04–0.68)	0.013
≥3 CVRF	4.19 (1.76–9.96)	0.001	3.79 (1.02–14.16)	0.047
Previous ASA taking	1.92 (0.89–4.15)	0.097	0.92 (0.26–3.29)	0.893
Severe symptoms	0.64 (0.31–1.55)	0.396
ST deviation	5.60 (2.44–12.86)	<0.001	6.27 (1.98–19.89)	0.002
PCI at admission	1.92 (0.90–4.10)	0.094	2.65 (0.75–9.37)	0.131
Angiographic lesions >50%	5.54 (2.07–14.83)	0.001	6.41 (1.41–29.24)	0.016

Previous non-STEACS: Previous non-ST elevation acute coronary syndrome. ≥3 CVRF: at least three cardiovascular risk factors. ASA: acetylsalicylic acid. OR: odds ratio. CI: confidence interval. PCI: percutaneous coronary intervention.